Erudio Healtherudio.com
Clinical trial · no report yet · Phase 1/Phase 2
NCT04113616
An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 When Administered Alone and in Combination With Low-Dose Cytarabine (LDAC) or Decitabine in Patients With Acute Myeloid Leukemia (AML)
- NCT04113616 ↗
- Terminated
- Kartos Therapeutics, Inc.
- Focused
We haven't built an HCP commentary report on NCT04113616 yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on NCT04113616 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 3 |
The trial
ClinicalTrials.gov- Official title
- An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 When Administered Alone and in Combination With Low-Dose Cytarabine (LDAC) or Decitabine in Patients With Acute Myeloid Leukemia (AML)
- Phase
- Phase 1/Phase 2
- Status
- Terminated
- Conditions
- Relapsed or Refractory Acute Myeloid Leukemia (AML); Acute Myeloid Leukemia (AML), Secondary to Myeloproliferative Neoplasms (MPN)
- Interventions
- KRT-232; Cytarabine; Decitabine
- Arms
- Part A - Arm 1 · Experimental
- Part A - Arm 2 · Experimental
- Part A - Arm 3 · Experimental
- Part B - Arm 1 · Experimental
- Part B - Arm 2 · Experimental
- Part B - Arm 3 · Experimental
- Enrollment
- 70
- Primary outcomes
- Part A: To determine KRT-232 recommended phase 2 dose (RP2D)
- Part B: To determine the RP2D of KRT-232
- Sponsor
- Kartos Therapeutics, Inc.
- Start
- Sep 25, 2019
- Primary completion
- Sep 27, 2023
- Results posted
- No
- Registry record
- NCT04113616 · updated Mar 22, 2024